Huntsman Cancer Institute | Strategic Alliance Partners

January 12, 2021

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of breast cancer.

December 21, 2020

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

December 11, 2020

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

December 01, 2020

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

August 04, 2020

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

May 07, 2020

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).